Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPCT-03 everolimus biomarker study in refractory solid tumors
NL-OMON40040Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of everolimus in Nonhematologic neoplasms (2 cohorts), sponsored by Netherlands Cancer Institute. Primary endpoints: Genomic predictors of response in part 1 and Progression free survival ratio in part 2. Started Aug 2012; status: recruiting.
02
Drugs
everolimus
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON40040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40040.